Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: Parallel study of 81 patients

Leukemia and Lymphoma

Volumn 55, Issue 10, 2014, Pages 2341-2348

  Xicoy, Blanca ^a   Ribera, Josep Maria ^a   Müller, Markus ^b   García, Olga ^a   Hoffmann, Christian ^c   Oriol, Albert ^a   Hentrich, Marcus ^d   Grande, Carlos ^e   Wasmuth, Jan Christian ^f   Esteve, Jordi ^g   Van Lunzen, Jan ^h   Del Potro, Eloy ⁱ   Knechten, Heribert ^j   Brunet, Salut ^k   Mayr, Christoph ^l   Escoda, Lourdes ^m   Schommers, Philipp ⁿ   Alonso, Natalia ^o   Vall Llovera, Ferran ^p   Pérez, Montserrat ^q   Morgades, Mireia ^a   González, José ^r   Fernández, Angeles ^s   Thoden, Jan ^t   Gökbuget, Nicola ^u   Hoelzer, Dieter ^u   Fätkenheuer, Gerd ⁿ   Wyen, Christoph ⁿ   more..

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b VIVANTES KLINIKUM NEUKÖLLN   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d Harlaching Hospital   (Germany)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f UNIVERSITY OF BONN   (Germany)

^g HOSPITAL CLÍNIC   (Spain)

^h UNIVERSITY OF HAMBURG   (Germany)

ⁱ HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^j Praxen Zentrum Blondelstrasse   (Germany)

^k HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^l Ärzteforum Seestrasse Medical Center   (Germany)

^m HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

ⁿ UNIVERSITY OF COLOGNE   (Germany)

^o HOSPITAL XERAL CALDE   (Spain)

^p HOSPITAL MÚTUA DE TERRASSA   (Spain)

^q HOSPITAL VIRGEN DE LA CONCHA   (Spain)

^r HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^s HOSPITAL XERAL CÍES   (Spain)

^t UNIVERSITY OF FREIBURG   (Germany)

^u UNIVERSITY HOSPITAL FRANKFURT   (Germany)

more..

Author keywords

Burkitt lymphoma or leukemia; HIV infection; Prognostic factors; Specific chemotherapy

Indexed keywords

CD4 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; TENIPOSIDE; VINCRISTINE; VINDESINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BONE MARROW; BONE MARROW SUPPRESSION; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CD4 LYMPHOCYTE COUNT; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; GERMANY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFECTION; LEUKEMIA; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SPAIN; THROMBOCYTOPENIA; CANCER STAGING; CLINICAL TRIAL; COHORT ANALYSIS; COMPLICATION; HIV INFECTIONS; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BURKITT LYMPHOMA; COHORT STUDIES; FEMALE; GERMANY; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; SPAIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84908397193     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.878933     Document Type: Article

References (36)

1. Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008;123:187-194.
2. Engels EA, Pfeiffer RM, Landgren O, et al. Immunologic and virologic predictors of AIDS-related non-Hodgkin's lymphoma in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr 2010;54:78-84.
3. Lim ST, Roksana K, Nathwani BN, et al. AIDS-related Burkitt's lymphoma versus large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol 2005;23:4430-4438.
4. Little RF, Pittaluga S, Nicole G, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003;101:4653-4659.
5. Sparano JA, Lee S, Chen MG, et al. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494). J Clin Oncol 2004;22:1491-1500.
6. Hoffman C, Wolf E, Wyen C, et al. AIDS associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective. Leuk Lymphoma 2006;47:1872-80.
7. Xicoy B, Ribera JM, Miralles P, et al. Comparison of CHOP treatment with specific short-intensive chemotherapy in AIDS-related Burkitt's lymphoma or leukemia. Med Clin (Barc) 2011;136:323-328.
8. Spina M, Jaeger U, Sparano JA, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin's lymphoma: pooled results from 3 phase 2 trials. Blood 2005;105:1891-1897.
9. Sparano JA, Lee JY, Kaplan LD, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin's lymphoma. Blood 2010;115:3008-3016.
10. Dunleavy K, Little R, Wayne AS, et al. Long term outcome of AIDS-related lymphoma treated with abbreviated cycles of EPOCH-R: a prospective study of 40 patients. Blood 2008;112(Suppl. 1):Abstract 3606.
11. Tirelli U, Spina M, Jaeger U, et al. Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: preliminary results of a phase I/II study. Recent Results Cancer Res 2002;159:149-153.
12. Boue F, Gabarre J, Gisselbrecht C, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol 2006;24:4123-4128.
13. Barta SK, Lee JY, Sparano JA, et al. Pooled analysis of AIDS malignancy consortium (AMC) trials evaluating rituximab plus either CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin's lymphoma. Blood 2010;116(Suppl. 1):Abstract 1797.
14. Montoto S, Wilson J, Shaw K, et al. Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma. AIDS 2010;24:851-856.
15. Wang ES, Straus DJ, Teruya-Feldstein J, et al. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer 2003;98:1196-1205.
16. Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 2002;94:1492-1499.
17. Fayad L, Thomas D, Romaguera J. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas. Clin Lymphoma Myeloma 2007;8(Suppl. 2):S57-S62.
18. Suzuki K, Nakazato T, Sanada Y, et al. Successful treatment with hyper-CVAD and highly active anti-retroviral therapy (HAART) for AIDS-related Burkitt lymphoma. Rinsho Ketsueki 2010;51:207-212.
19. Galicier L, Fieschi C, Borie R, et al. Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study. Blood 2007;110:2846-2854.
20. Oriol A, Ribera JM, Bergua J, et al. High-dose chemotherapy and immunotherapy in adult Burkitt's lymphoma: comparison of results in human immunodeficiency virus-infected and non-infected patients. Cancer 2008;113:117-125.
21. Hoelzer D, Hiddemann W, Baumann A, et al. High survival rate in adult Burkitt's lymphoma/leukemia and diffuse large B cell lymphoma with mediastinal involvement. Blood 2007;110(Suppl. 1): Abstract 518.
22. Hoelzer D, Ludwig WD, Thiel E, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 1996;87:495-508.
23. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;10:1419-1432.
24. The International non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994.
25. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection:2006 recommendations of the International AIDS Society-USA panel. JAMA 2006;296:827-843.
26. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
27. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: analysis and examples. Br J Cancer 1977;35:1-39.
28. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187-220.
29. Vaccher E, Spina M, di Gennaro G, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin's lymphoma. Cancer 2001;91:155-163.
30. Kaplan LD, Straus DJ, Testa MA, et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. N Engl J Med 2006;336:1641-1648.
31. Straus DJ, Huang J, Testa MA, et al. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142-low-dose versus standard dose m-BACOD plus granulocyte macrophage colony-stimulating factor. J Clin Oncol 1998;16:3601-3606.
32. Oriol A, Ribera JM, Brunet S, et al. Highly active antiretroviral therapy and outcome of AIDS-related Burkitt's lymphoma or leukemia. Results of the PETHEMA LAL3/97 study. Haematologica 2005;90:990-992.
33. Oriol A, Ribera JM, Esteve J, et al. Lack of influence of human imunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study. Haematologica 2003;88:445-453.
34. Kaplan L, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or wtihout rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 2005;106:1538-1543.
35. Ribera JM, Oriol A, Morgades M, et al. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol 2008;140:411-419.
36. Ferreri AJ, Bruno Ventre M, Donadoni G, et al. Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphoma. Br J Haematol 2012;159:252-255.